+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Next Generation Sequencing Market Size, Share & Trends Analysis Report by Technology (Whole Exome Sequencing, Targeted Sequencing & Resequencing), Product (Platforms, Consumables), Application, Workflow, End-use, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 90 Pages
  • March 2024
  • Region: United States
  • Grand View Research
  • ID: 5950105
Description Jump to:
The U.S. next generation sequencing market size is anticipated to reach USD 11.82 billion by 2030, expanding at a CAGR of 20.14% from 2024 to 2030. Increasing applications of next generation sequencing (NGS) in drug discovery, diagnostics, and personalized medicine, as well as the growing prevalence of cancer and other genetic disorders. In addition, rising cardiovascular diseases is another factor driving the U.S. market’s growth.

According to Centers for Disease Control and Prevention (CDC), heart disease remains the leading cause of death across various demographics in the U.S., including men, women, and individuals of most racial and ethnic backgrounds. On average, a person dies of cardiovascular disease every 33 seconds in the U.S. Sequencing can be employed in cardiovascular genetics to identify genetic risk factors for conditions like familial hypercholesterolemia, cardiomyopathies, and arrhythmias. It enables early detection of individuals at risk and facilitates personalized treatment plans.

Continuous innovations and improvements in NGS technologies, such as sequencing platforms, bioinformatics tools, and sample preparation methods, drive market growth. Enhanced sequencing speed, accuracy, and cost-effectiveness make NGS more accessible and applicable across diverse research and clinical applications. The expanding utility of sequencing techniques in clinical diagnostics, including oncology, rare diseases, genetic disorders, and infectious diseases, is a significant driver of market growth. NGS enables precise and comprehensive genetic analysis, leading to improved diagnosis, treatment selection, and patient care.

The COVID-19 pandemic has significantly affected the U.S. NGS market. As healthcare providers focus on managing the pandemic, routine medical procedures, including genetic testing, have been postponed or canceled. This has caused a decline in the demand for NGS tests in the country. However, the pandemic has also highlighted the importance of genetic testing and its potential in managing and treating diseases. As a result, there has been a renewed interest in NGS-based research and development, which is expected to drive the market’s growth in the coming years. Furthermore, the increased demand for COVID-19 testing has led to the development of new NGS-based diagnostic tests. These tests are expected to play a crucial role in the early detection and management of the disease.

The U.S. NGS market’s growth is driven by the substantial cost associated with NGS technologies. The initial investment in sequencing instruments, reagents, and infrastructure can be prohibitively high for many research laboratories, academic institutions, and smaller healthcare facilities. Additionally, the ongoing operational expenses and maintenance costs further strain limited budgets, hindering access to NGS technology. Sequencing generates vast amounts of complex data, posing significant challenges in storage, analysis, and interpretation. Managing terabytes to petabytes of sequencing data requires robust computational resources and sophisticated bioinformatics tools. Moreover, ensuring data integrity, security, and compliance with privacy regulations adds another layer of complexity to NGS data management.

U.S. Next Generation Sequencing Market Report Highlights

  • Consumables dominated the product segment in 2023 owing to the increasing demand for high-quality and reliable sequencing products
  • The oncology application segment held the largest revenue share of 26.67% in 2023. On the other hand, the consumer genomics segment is expected to grow at the highest CAGR by 2030.
  • In 2023, targeted sequencing & resequencing dominated the technology segment with a revenue share of 71.14% and is expected to grow at the highest CAGR by 2030
  • In 2023, sequencing dominated the workflow segment with a share of 57.60% while NGS data analysis is expected to grow at the highest CAGR from 2024 to 2030
  • Academic research dominated the end-use segment with a revenue share of 50.49% in 2023

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Technology
1.2.2. Product
1.2.3. Application
1.2.4. Workflow
1.2.5. End-use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Decreasing costs for genetic sequencing
3.2.1.2. Development of companion diagnostics and personalized medicine
3.2.1.3. Rise in competition among prominent market entities
3.2.1.4. Rising clinical opportunity for NGS technology
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of computational efficiency for data management
3.2.2.2. Challenges associated with NGS implementation
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. NGS Market: Technology Business Analysis
4.1. Segment Dashboard
4.2. U.S. NGS Market Technology Movement Analysis
4.3. U.S. NGS Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Targeted Sequencing & Resequencing
4.4.1. Targeted sequencing & resequencing market estimates and forecast, 2018 - 2030 (USD Million)
4.4.1.1. DNA-based targeted sequencing & resequencing
4.4.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2018 - 2030 (USD Million)
4.4.1.2. RNA-based targeted sequencing & resequencing
4.4.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2018 - 2030 (USD Million)
4.5. Whole Genome Sequencing
4.5.1. Whole genome sequencing market estimates and forecast, 2018 - 2030 (USD Million)
4.6. Whole Exome Sequencing
4.6.1. Whole exome sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5. U.S. NGS Market: Product Business Analysis
5.1. Segment Dashboard
5.2. U.S. NGS Market Product Movement Analysis
5.3. U.S. NGS Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.4. Platforms
5.4.1. Platforms market estimates and forecast, 2018 - 2030 (USD Million)
5.4.1.1. Sequencing
5.4.1.1.1. Sequencing platforms market estimates and forecast, 2018 - 2030 (USD Million)
5.4.1.2. Data Analysis
5.4.1.2.1. Data analysis platforms market estimates and forecast, 2018 - 2030 (USD Million
5.5. Consumables
5.5.1. Consumables market estimates and forecast, 2018 - 2030 (USD million)
5.5.2. Sample Preparation
5.5.2.1. Sample preparation market estimates and forecast, 2018 - 2030 (USD Million)
5.5.3. Target Enrichment
5.5.3.1. Target enrichment market estimates and forecast, 2018 - 2030 (USD Million)
5.5.4. Others
5.5.4.1. Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6. U.S. NGS Market: Application Business Analysis
6.1. Segment Dashboard
6.2. U.S. NGS Market Application Movement Analysis
6.3. U.S. NGS Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology market estimates and forecast, 2018 - 2030 (USD Million)
6.4.2. Diagnostics & Screening
6.4.2.1. Diagnostics & screening market estimates and forecast, 2018 - 2030 (USD Million)
6.4.2.2. Oncology screening
6.4.2.2.1. Oncology screening market estimates and forecast, 2018 - 2030 (USD Million)
6.4.2.2.2. Sporadic Cancer
6.4.2.2.2.1. Sporadic cancer screening market estimates and forecast, 2018 - 2030 (USD Million)
6.4.2.2.3. Inherited Cancer
6.4.2.2.3.1. Inherited cancer screening market estimates and forecast, 2018 - 2030 (USD Million)
6.4.2.3. Companion diagnostics
6.4.2.3.1. Companion diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
6.4.2.4. Other diagnostics
6.4.2.4.1. Other diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
6.4.3. Research Studies
6.4.3.1. Research studies market estimates and forecast, 2018 - 2030 (USD Million)
6.5. Clinical Investigation
6.5.1. Clinical investigation market estimates and forecast, 2018 - 2030 (USD Million)
6.5.2. Infectious Diseases
6.5.2.1. Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
6.5.3. Idiopathic Diseases
6.5.3.1. Idiopathic diseases market estimates and forecast, 2018 - 2030 (USD Million)
6.5.4. Inherited Diseases
6.5.4.1. Inherited diseases market estimates and forecast, 2018 - 2030 (USD Million)
6.5.5. Non-Communicable/Other Diseases
6.5.5.1. Non-communicable/other diseases market estimates and forecast, 2018 - 2030 (USD Million)
6.6. Reproductive Health
6.6.1. Reproductive health market estimates and forecast, 2018 - 2030 (USD Million)
6.6.2. NIPT
6.6.2.1. NIPT market estimates and forecast, 2018 - 2030 (USD Million)
6.6.2.2. Aneuploidy
6.6.2.2.1. Aneuploidy market estimates and forecast, 2018 - 2030 (USD Million)
6.6.2.3. Microdeletions
6.6.2.3.1. Microdeletions market estimates and forecast, 2018 - 2030 (USD Million)
6.6.3. PGT
6.6.3.1. PGT market estimates and forecast, 2018 - 2030 (USD Million)
6.6.4. Newborn Genetic Screening
6.6.4.1. Newborn genetic screening market estimates and forecast, 2018 - 2030 (USD Million)
6.6.5. Single Gene Analysis
6.6.5.1. Single gene analysis market estimates and forecast, 2018 - 2030 (USD Million)
6.7. HLA Typing/Immune System Monitoring
6.7.1. HLA typing/immune system monitoring market estimates and forecast, 2018 - 2030 (USD Million)
6.8. Metagenomics, Epidemiology & Drug Development
6.8.1. Metagenomics, epidemiology & drug development market estimates and forecast, 2018 - 2030 (USD Million)
6.9. Agrigenomics & Forensics
6.9.1. Agrigenomics & forensics market estimates and forecast, 2018 - 2030 (USD Million)
6.10. Consumer Genomics
6.10.1. Consumer genomics market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7. U.S. NGS Market: Workflow Business Analysis
7.1. Segment Dashboard
7.2. U.S. NGS Market Workflow Movement Analysis
7.3. U.S. NGS Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
7.4. Pre-sequencing
7.4.1. Pre-sequencing market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. Library Preparation
7.4.2.1. Library preparation market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2.2. NGS Library Preparation Kits
7.4.2.2.1. NGS library preparation kits market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2.3. Semi-automated Library Preparation
7.4.2.3.1. Semi-automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2.4. Automated Library Preparation
7.4.2.4.1. Automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. Others
7.4.3.1. Others market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Sequencing
7.5.1. Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
7.6. Data Analysis
7.6.1. Data analysis market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. NGS Primary Data Analysis
7.6.2.1. NGS primary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. NGS Secondary Data Analysis
7.6.3.1. NGS secondary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
7.6.4. NGS Tertiary Data Analysis
7.6.4.1. NGS tertiary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8. U.S. NGS Market: End-use Business Analysis
8.1. Segment Dashboard
8.2. U.S. NGS Market End-use Movement Analysis
8.3. U.S. NGS Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
8.4. Academic Research
8.4.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
8.5. Clinical Research
8.5.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
8.6. Hospitals & Clinics
8.6.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
8.7. Pharmaceutical & Biotech Entities
8.7.1. Pharmaceutical & biotech entities market estimates and forecast, 2018 - 2030 (USD Million)
8.8. Other Users
8.8.1. Other users market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2023
9.4. Participant’s Overview
9.4.1. Illumina
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. QIAGEN
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Thermo Fisher Scientific, Inc.
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Bio-Rad Laboratories, Inc.
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Oxford Nanopore Technologies
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Pacific Biosciences
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Agilent Technologies, Inc
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. BGI
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. F. Hoffmann-La Roche AG
9.4.9.1. Overview
9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Eurofins Scientific
9.4.10.1. Overview
9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. NGS market, by technology, 2018 - 2030 (USD Million)
Table 4 U.S. NGS market, by product, 2018 - 2030 (USD Million)
Table 5 U.S. NGS market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. NGS market, by workflow, 2018 - 2030 (USD Million)
Table 7 U.S. NGS market, by end-use, 2018 - 2030 (USD Million)
Table 8 Key companies undergoing expansions
Table 9 Key companies undergoing acquisitions
Table 10 Key companies undergoing collaborations
Table 11 Key companies launching new products
Table 12 Key companies undertaking other strategies
List of Figures
Fig. 1 U.S. NGS market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook
Fig. 13 U.S. NGS market driver analysis
Fig. 14 U.S. NGS market restraint analysis
Fig. 15 U.S. NGS market: Porter's analysis
Fig. 16 U.S. NGS market: PESTEL analysis
Fig. 17 U.S. NGS market: Technology movement analysis
Fig. 18 U.S. NGS market: Technology outlook and key takeaways
Fig. 19 Targeted sequencing & resequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 DNA-based targeted sequencing & resequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 RNA-based targeted sequencing & resequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Whole genome sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Whole exome sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 U.S. NGS market: Product outlook key takeaways
Fig. 25 U.S. NGS market: Product movement analysis
Fig. 26 Platforms market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Sequencing platforms market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Data analysis platforms market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Consumables market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Sample preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Target enrichment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 U.S. NGS Market: Application Movement Analysis
Fig. 34 U.S. NGS market: Application outlook and key takeaways
Fig. 35 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Diagnostics & screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Oncology screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Sporadic cancer screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Inherited cancer screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Companion diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Other diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Research studies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Clinical investigation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Idiopathic diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Inherited diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Non-communicable/other diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Reproductive health market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 NIPT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Aneuploidy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Microdeletions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 PGT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Newborn genetic screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Single gene analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 HLA typing/immune system monitoring market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Metagenomics, epidemiology & drug development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Agrigenomics & forensics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Consumer genomics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 U.S. NGS market: Workflow movement analysis
Fig. 60 U.S. NGS market: Workflow outlook and key takeaways
Fig. 61 Pre-sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 NGS library preparation kits market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Semiautomated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 NGS data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 NGS primary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 NGS secondary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 NGS tertiary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 U.S. NGS market End-use outlook key takeaways
Fig. 73 U.S. NGS market: End-use movement analysis
Fig. 74 Academic research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Pharmaceutical & biotech entities market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Other users market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Market participant categorization
Fig. 80 Company market positioning
Fig. 81 Strategy framework

Companies Mentioned

  • Illumina
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Agilent Technologies, Inc
  • BGI
  • F. Hoffmann-La Roche AG
  • Eurofins Scientific

Methodology

Loading
LOADING...

Related Topics

Related Reports

U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report by Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), Technology, Application, End-use, and Segment Forecasts, 2025-2030 - Product Image

U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report by Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), Technology, Application, End-use, and Segment Forecasts, 2025-2030

  • Report
  • 90 Pages
  • United States
From
Next-generation Sequencing Library Preparation Market Size, Share & Trends Analysis Report By Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing), By Product, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Next-generation Sequencing Library Preparation Market Size, Share & Trends Analysis Report By Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing), By Product, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Next Generation Sequencing Market Analysis & Forecast to 2024-2034 - Product Image

Next Generation Sequencing Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Next-Generation Sequencing Market: Industry Outlook by Offering Application End User - Global Forecast to 2031 - Product Image

Next-Generation Sequencing Market: Industry Outlook by Offering Application End User - Global Forecast to 2031

  • Report
  • 451 Pages
  • Global
From
Next-Generation Sequencing Sample Preparation Market by Workflow, Application, End User - Global Forecast 2025-2030 - Product Image

Next-Generation Sequencing Sample Preparation Market by Workflow, Application, End User - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From

About the Market

The Next Generation Sequencing (NGS) market is a subset of the biotechnology industry that focuses on the development and application of high-throughput sequencing technologies. NGS technologies enable the rapid and cost-effective sequencing of large amounts of DNA or RNA, allowing for the analysis of genetic variation and gene expression. This technology has been used to identify and characterize genetic mutations, to study gene expression, and to develop new diagnostics and therapeutics. NGS has also been used to study the evolution of viruses and bacteria, and to identify new species. The NGS market is highly competitive, with a number of companies offering a range of sequencing technologies and services. Some of the major players in the market include Illumina, Thermo Fisher Scientific, BGI, Pacific Biosciences, Oxford Nanopore Technologies, and 10x Genomics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.